Home > Research > Publications & Outputs > Liposome delivery systems for the treatment of ...

Electronic data

Links

Text available via DOI:

View graph of relations

Liposome delivery systems for the treatment of Alzheimer’s disease

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Liposome delivery systems for the treatment of Alzheimer’s disease. / Ross, Callum; Taylor, Mark Neville; Fullwood, Nigel James et al.
In: International Journal of Nanomedicine, Vol. 2018, No. 13, 12.12.2018, p. 8507-8522.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Ross, C, Taylor, MN, Fullwood, NJ & Allsop, D 2018, 'Liposome delivery systems for the treatment of Alzheimer’s disease', International Journal of Nanomedicine, vol. 2018, no. 13, pp. 8507-8522. https://doi.org/10.2147/IJN.S183117

APA

Ross, C., Taylor, M. N., Fullwood, N. J., & Allsop, D. (2018). Liposome delivery systems for the treatment of Alzheimer’s disease. International Journal of Nanomedicine, 2018(13), 8507-8522. https://doi.org/10.2147/IJN.S183117

Vancouver

Ross C, Taylor MN, Fullwood NJ, Allsop D. Liposome delivery systems for the treatment of Alzheimer’s disease. International Journal of Nanomedicine. 2018 Dec 12;2018(13):8507-8522. doi: 10.2147/IJN.S183117

Author

Ross, Callum ; Taylor, Mark Neville ; Fullwood, Nigel James et al. / Liposome delivery systems for the treatment of Alzheimer’s disease. In: International Journal of Nanomedicine. 2018 ; Vol. 2018, No. 13. pp. 8507-8522.

Bibtex

@article{40bad3e961a8400cb186bb9862e59a15,
title = "Liposome delivery systems for the treatment of Alzheimer{\textquoteright}s disease",
abstract = "Alzheimer{\textquoteright}s disease (AD) will affect around 115 million people worldwide by the year 2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs for AD only temporarily alleviate symptoms and do not slow the inevitable progression of this disease. New drugs are required that act on key pathologies in order to arrest or reverse cognitive decline. However, there has been a spectacular failure rate in clinical trials of conventional small molecule drugs or biological agents. Targeted nanoliposomes represent a viable and promising drug delivery system for AD that have not yet reached clinical trials. They are biocompatible, highly flexible, and have the potential to carry many different types of therapeutic molecules across the blood–brain barrier (BBB) and into brain cells. They can be tailored to extend blood circulation time and can be directed against individual or multiple pathological targets. Modifications so far have included the use of brain-penetrating peptides, together with Aβ-targeting ligands, such as phosphatidic acid, curcumin, and a retro-inverted peptide that inhibits Aβ aggregation. Combining several modifications together into multifunctional liposomes is currently a research area of great interest. This review focuses on recent liposomal approaches to AD therapy, including mechanisms involved in facilitating their passage across the BBB, and the evaluation of new therapeutic agents for blocking Aβ and/or tau aggregation. ",
keywords = "amyloid, blood–brain barrier, cell-penetrating peptides, neurofibrillary tangles, senile plaques, tau",
author = "Callum Ross and Taylor, {Mark Neville} and Fullwood, {Nigel James} and David Allsop",
year = "2018",
month = dec,
day = "12",
doi = "10.2147/IJN.S183117",
language = "English",
volume = "2018",
pages = "8507--8522",
journal = "International Journal of Nanomedicine",
issn = "1178-2013",
publisher = "Dove Medical Press Ltd.",
number = "13",

}

RIS

TY - JOUR

T1 - Liposome delivery systems for the treatment of Alzheimer’s disease

AU - Ross, Callum

AU - Taylor, Mark Neville

AU - Fullwood, Nigel James

AU - Allsop, David

PY - 2018/12/12

Y1 - 2018/12/12

N2 - Alzheimer’s disease (AD) will affect around 115 million people worldwide by the year 2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs for AD only temporarily alleviate symptoms and do not slow the inevitable progression of this disease. New drugs are required that act on key pathologies in order to arrest or reverse cognitive decline. However, there has been a spectacular failure rate in clinical trials of conventional small molecule drugs or biological agents. Targeted nanoliposomes represent a viable and promising drug delivery system for AD that have not yet reached clinical trials. They are biocompatible, highly flexible, and have the potential to carry many different types of therapeutic molecules across the blood–brain barrier (BBB) and into brain cells. They can be tailored to extend blood circulation time and can be directed against individual or multiple pathological targets. Modifications so far have included the use of brain-penetrating peptides, together with Aβ-targeting ligands, such as phosphatidic acid, curcumin, and a retro-inverted peptide that inhibits Aβ aggregation. Combining several modifications together into multifunctional liposomes is currently a research area of great interest. This review focuses on recent liposomal approaches to AD therapy, including mechanisms involved in facilitating their passage across the BBB, and the evaluation of new therapeutic agents for blocking Aβ and/or tau aggregation.

AB - Alzheimer’s disease (AD) will affect around 115 million people worldwide by the year 2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs for AD only temporarily alleviate symptoms and do not slow the inevitable progression of this disease. New drugs are required that act on key pathologies in order to arrest or reverse cognitive decline. However, there has been a spectacular failure rate in clinical trials of conventional small molecule drugs or biological agents. Targeted nanoliposomes represent a viable and promising drug delivery system for AD that have not yet reached clinical trials. They are biocompatible, highly flexible, and have the potential to carry many different types of therapeutic molecules across the blood–brain barrier (BBB) and into brain cells. They can be tailored to extend blood circulation time and can be directed against individual or multiple pathological targets. Modifications so far have included the use of brain-penetrating peptides, together with Aβ-targeting ligands, such as phosphatidic acid, curcumin, and a retro-inverted peptide that inhibits Aβ aggregation. Combining several modifications together into multifunctional liposomes is currently a research area of great interest. This review focuses on recent liposomal approaches to AD therapy, including mechanisms involved in facilitating their passage across the BBB, and the evaluation of new therapeutic agents for blocking Aβ and/or tau aggregation.

KW - amyloid

KW - blood–brain barrier

KW - cell-penetrating peptides

KW - neurofibrillary tangles

KW - senile plaques

KW - tau

U2 - 10.2147/IJN.S183117

DO - 10.2147/IJN.S183117

M3 - Journal article

VL - 2018

SP - 8507

EP - 8522

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1178-2013

IS - 13

ER -